Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35.95
56.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Jiangsu Hengrui Pharmaceuticals Co Ltd
Jiangsu Hengrui Pharmaceuticals Co Ltd
Non-Reccuring Items
Jiangsu Hengrui Pharmaceuticals Co Ltd
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Non-Reccuring Items
¥778.9k
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Non-Reccuring Items
¥12.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Non-Reccuring Items
¥4.8m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Non-Reccuring Items
¥3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Non-Reccuring Items
¥146.4k
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View
Nestled in the throbbing economic heart of China's Jiangsu province, Jiangsu Hengrui Pharmaceuticals Co Ltd has carved a niche as a formidable player in the global pharmaceutical landscape. Established in 1970, this company has evolved from its humble beginnings into a powerhouse known for its relentless focus on research and development, a keystone in its operational strategy. Hengrui has built a diverse portfolio of products, primarily focusing on oncological, cardiovascular, and anti-diabetic therapeutics. The company leverages its state-of-the-art R&D facilities and a team of top-tier scientists to innovate and advance new treatment solutions, which are then patented to ensure exclusivity and competitive market positioning. In addition to its robust R&D-driven pipeline, Hengrui thrives through strategic collaborations and international partnerships that enhance its market reach and deepen its competitive moat. Revenue generation springs from a dual-engine model: sales of proprietary drugs and a burgeoning generic drug segment that ensures steady cash flow. Furthermore, Hengrui's ability to navigate the intricate regulatory landscapes of different countries enables it to market its innovative therapies globally, thus broadening its revenue streams. With an eye toward sustainable growth, the company continually reinvests a significant portion of its profits back into R&D, sustaining its cycle of innovation and market leadership, while also playing a vital role in meeting global healthcare needs.
See Also
What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Non-Reccuring Items?
Non-Reccuring Items
778.9k
CNY
Based on the financial report for Sep 30, 2024, Jiangsu Hengrui Pharmaceuticals Co Ltd's Non-Reccuring Items amounts to 778.9k CNY.
What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
-19%
Over the last year, the Non-Reccuring Items growth was -92%. The average annual Non-Reccuring Items growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been -46% over the past three years , -19% over the past five years .
You don't have any saved screeners yet
